• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Non-TNF-targeted therapies more effective than anti-TNF agents in uncontrolled rheumatoid arthritis

byMilana Bogorodskaya, MDandMichael Milligan
September 24, 2016
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The addition of a non-TNF-targeted biologic therapy is superior to the addition of an anti-TNF biologic therapy in patients with rheumatoid arthritis that is not well controlled with a first-line anti-TNF medication.

2. There was no difference in serious adverse events or infections between the two classes of therapeutics.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Patients with poorly controlled rheumatoid arthritis (RA) pose a significant challenge for the medical community. This study sought to determine whether patients with RA that is not controlled with a first-line anti-TNF therapy would benefit more from the addition of another anti-TNF therapy (adalimumab, etanercept, infliximab, etc.) or by a non-TNF-targeted therapy (abatacept, rituximab, etc.). While the specific biologic therapy in each class was up to the discretion of treating physicians, this study found that patients who received a non-TNF-targeted therapy had higher rates of response and lower overall levels of ongoing disease activity.

This study shows a clear benefit of non-TNF-targeted therapies for patients with poorly controlled RA. Its results are strengthened by a rigorous randomization protocol and follow-up of disease progression over 52 weeks. However, the study was conducted in a non-blinded fashion which could potentially add to physician and patient bias, especially given the subjective nature of the efficacy. Further, large-scale randomized controlled trials are needed to further evaluate the validity of these findings.

Click to read the study in JAMA

Relevant Reading: Rheumatoid Arthritis

RELATED REPORTS

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis

In-Depth [randomized controlled trial]: This study was an open-label randomized clinical trial that enrolled 300 patients with rheumatoid arthritis that was not controlled on a TNF-alpha inhibitor. These patients were randomized to receive an additional anti-TNF drug or an additional non-TNF-targeted drug. Patients were followed for a total of 52 weeks. The primary outcome was the proportion of patients who achieved good or moderate response to therapy at 24 weeks. Therapy response was determined by subjective patient ratings on the European League Against Rheumatism (EULAR) scale. Secondary outcomes consisted of EULAR response at 12 and 52 weeks, achievement of low disease activity (DAS28 <3.2) or remission (DAS28 <2.6), serious adverse events, and serious infections.

The results demonstrated that patients receiving a non-TNF-targeted biologic had higher rates of good or moderate EULAR response at 24 weeks (69% vs. 52%, OR 2.06; p = 0.004). This difference in response remained significant at 52 weeks, when 41% of patients in the non-TNF-targeted biologic cohort reported low disease activity compared to only 23% in the anti-TNF therapy arm (OR 2.26, p = 0.003). There was no statistical difference in adverse events or serious infections between the two groups.

 

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: rheumatoid arthritis
Previous Post

Early food introduction in infant diets associated with lower risk of allergic disease

Next Post

2 Minute Medicine Rewind September 26, 2016

RelatedReports

Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

September 14, 2022
2 Minute Medicine Rewind January 28, 2019
Chronic Disease

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

August 26, 2022
2 Minute Medicine Rewind January 28, 2019
Chronic Disease

Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis

August 3, 2022
2 Minute Medicine Rewind January 28, 2019
Cardiology

Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis

February 2, 2022
Next Post
Combined MRI and NIH stroke scores may predict stroke prognosis

2 Minute Medicine Rewind September 26, 2016

Few older adolescents meet recommended levels of physical activity

Few older adolescents meet recommended levels of physical activity

History of maternal anorexia linked to small infant size

Nausea and vomiting inversely associated with pregnancy loss

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options